Literature DB >> 11438158

Raynaud's phenomenon.

J A Block1, W Sequeira.   

Abstract

Raynaud's phenomenon is characterised by episodic vasospasm of the fingers and toes typically precipitated by exposure to cold. Mild Raynaud's is common and is not usually a harbinger of clinically important disability; its onset, however, can be startling and uncomfortable for patients, and the well recognised association in some cases with systemic rheumatic conditions often precipitates aggressive assessments for underlying diseases. Advances in vascular physiology have shed light on the role of the endothelium as well as endothelium-independent mechanisms in the altered vasoregulation of Raynaud's. We review clinical aspects of the disorder and new insights with respect to pathophysiology, and we discuss potential new therapeutics based on the disease mechanism, such as prostacyclin analogues, serotonin antagonists, and calcitonin gene-related peptides.

Entities:  

Mesh:

Year:  2001        PMID: 11438158     DOI: 10.1016/S0140-6736(00)05118-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  80 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod.

Authors:  Raffaela Bertoli; François Girardin; Stefan Russmann; Bernhard H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  2003-01-29       Impact factor: 2.953

3.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Authors:  Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

4.  The usefulness of power Doppler ultrasonography in differentiating primary and secondary Raynaud's phenomenon.

Authors:  Sang Il Lee; Sang Yong Lee; Wan Hee Yoo
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

Review 5.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

6.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 7.  Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

Review 8.  Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment.

Authors:  Deana Lazaro
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

10.  Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial.

Authors:  Ibo H Souwer; Jacobus H J Bor; Paul Smits; Antoine L M Lagro-Janssen
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.